Taysha Gene Therapies Inc
TSHA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.61B
Close$
$0.28
93.6% downside
Current Fair Value
93.6% downsideOvervalued by 93.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.61 Billion |
|---|---|
| Enterprise Value | $1.21 Billion |
| Earnings per Share | $-0.34 |
| Beta | 1.17 |
| Outstanding Shares | 369,044,040 |
Return
| Return on Equity | -38.64% |
|---|---|
| Return on Assets | -31.81% |
| Return on Invested Capital | -34.37% |
Valuation & Multiples
| P/E Ratio | -9.77 |
|---|---|
| PEG | -13.3 |
| Price to Sales | - |
| Price to Book Ratio | 4.36 |
| Enterprise Value to Revenue | 220.45 |
| Enterprise Value to EBIT | -7.92 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.13
Consensus analyst estimateRevenue Estimate
$755,556
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 22.54% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.14%▼ 81.63% |
|---|---|
| Total Invested | $2.36M▼ 99.89% |
| Investors Holding | 14▼ 202.00% |
About Taysha Gene Therapies Inc
38 employees
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined i...